These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21880182)

  • 1. Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.
    Liu Q; Jernigan D; Zhang Y; Fatatis A
    Chin J Cancer; 2011 Sep; 30(9):612-9. PubMed ID: 21880182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor.
    Dolloff NG; Russell MR; Loizos N; Fatatis A
    Cancer Res; 2007 Jan; 67(2):555-62. PubMed ID: 17234763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.
    Russell MR; Liu Q; Lei H; Kazlauskas A; Fatatis A
    Cancer Res; 2010 May; 70(10):4195-203. PubMed ID: 20442296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis.
    Russell MR; Liu Q; Fatatis A
    Clin Cancer Res; 2010 Oct; 16(20):5002-10. PubMed ID: 20813817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor.
    Dolloff NG; Shulby SS; Nelson AV; Stearns ME; Johannes GJ; Thomas JD; Meucci O; Fatatis A
    Oncogene; 2005 Oct; 24(45):6848-54. PubMed ID: 16007172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
    Gerber DE; Gupta P; Dellinger MT; Toombs JE; Peyton M; Duignan I; Malaby J; Bailey T; Burns C; Brekken RA; Loizos N
    Mol Cancer Ther; 2012 Nov; 11(11):2473-82. PubMed ID: 22933705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.
    Liang M; Wang B; Schneider A; Vainshtein I; Roskos L
    AAPS J; 2020 Nov; 23(1):4. PubMed ID: 33210183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.
    Park SH; Keller ET; Shiozawa Y
    Calcif Tissue Int; 2018 Feb; 102(2):152-162. PubMed ID: 29094177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
    Stock P; Monga D; Tan X; Micsenyi A; Loizos N; Monga SP
    Mol Cancer Ther; 2007 Jul; 6(7):1932-41. PubMed ID: 17604334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
    Liu Q; Russell MR; Shahriari K; Jernigan DL; Lioni MI; Garcia FU; Fatatis A
    Cancer Res; 2013 Jun; 73(11):3297-305. PubMed ID: 23536554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal sequence of bone target drugs in metastatic prostatic cancer.
    Gernone A; Bordonaro S; Tralongo P
    Expert Rev Anticancer Ther; 2015; 15(8):923-9. PubMed ID: 26070344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
    Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
    Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer.
    Zhang X
    Cancer Commun (Lond); 2019 Nov; 39(1):76. PubMed ID: 31753020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative evaluation of bone scanning, histological and biological studies of bone marrow in the staging of prostate cancer].
    Aguirre F; Díaz González R; Leiva O; Mayor J; Borobia V
    Actas Urol Esp; 1981; 5(2):99-104. PubMed ID: 7270287
    [No Abstract]   [Full Text] [Related]  

  • 16. Agents targeting prostate cancer bone metastasis.
    Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary therapeutic approaches targeting bone complications in prostate cancer.
    Lee RJ; Saylor PJ; Smith MR
    Clin Genitourin Cancer; 2010 Dec; 8(1):29-36. PubMed ID: 21208853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
    Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
    Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
    [No Abstract]   [Full Text] [Related]  

  • 20. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
    Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.